Impact of Opioid Dose Reduction and Risk Mitigation Initiatives on Chronic Opioid Therapy Patients at Higher Risk for Opioid-Related Adverse Outcomes. Issue 12 (6th December 2017)

• Record Type: Journal Article
• Authors: Thakral, Manu; Walker, Rod L; Saunders, Kathleen; Shortreed, Susan M; Dublin, Sascha; Parchman, Michael; Hansen, Ryan N; Ludman, Evette; Sherman, Karen J; Von Korff, Michael
• Is Part Of: Pain medicine. Volume 19:Issue 12(2018)
• Page Start: 2450
• Page End: 2458
• Publication Date: 2017-12-06
• Subjects: opiates -- overdose -- risk mitigation -- addiction -- mental disorders -- prescription opioids; Pain -- Periodicals; Pain -- Treatment -- Periodicals; Analgesics -- Periodicals; Pain -- Periodicals; Pain Management -- Periodicals; Douleur -- Périodiques; Douleur -- Traitement -- Périodiques; Analgésiques -- Périodiques; Analgésique; Soulagement de la douleur; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.047205
• DOI: 10.1093/pm/pnx293
• Languages: English
• ISSNs: 1526-2375

Abstract

Abstract: Objective: We aimed to determine if opioid risk reduction initiatives including dose reduction and risk mitigation strategies for chronic noncancer pain patients receiving chronic opioid therapy (COT) had a differential impact on average daily opioid doses of COT patients at higher risk for opioid-related adverse outcomes compared with lower-risk patients. Design: Interrupted time series. Setting: Group Health Cooperative (GH), a health care delivery system and insurance within Washington State, between 2006 and 2014. Population: GH enrollees on COT defined as receiving a supply of 70 or more days of opioids within 90 days using electronic pharmacy data for filled prescriptions. Methods: We compared the average daily morphine equivalent doses (MED) of COT patients with and without each of the following higher-risk characteristics: mental disorders, substance use disorders, sedative use, and male gender. Results: In all four pairwise comparisons, the higher-risk subgroup had a higher average daily MED than the lower-risk subgroup across the study period. Adjusted for covariates, modest differences in the annual rate of reduction in average daily MED were noted between higher- and lower-risk subgroups in three pairwise comparisons: those with mental disorders vs without (–8.2 mg/y vs –5.2 mg/y, P = 0.005), with sedative use vs without (–9.2 mg/y vs –5.8 mg/y, P = 0.004); mg), in men vs women (–8.8 mg/y vs –5.9 mg/y, P = 0.01). Conclusion: Using clinical policy initiatives in a health care system, dose reductions were achieved among COT patients at higher risk for opioid-related adverse outcomes that were at least as large as those among lower-risk patients.